A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia

This trial is testing a three-drug combination — ivosidenib, azacitidine, and venetoclax — as initial treatment for older patients with a form of acute myeloid leukemia (AML) that has a specific genetic mutation called IDH1. AML is a fast-growing blood cancer, and targeted therapies like ivosidenib block the IDH1 mutation that drives tumor growth. **You may be eligible if...** - You are 60 years old or older - You have been newly diagnosed with acute myeloid leukemia (AML) - Your leukemia has the IDH1-R132 mutation (confirmed by genetic testing) - You have not yet received treatment for AML **You may NOT be eligible if...** - You have already received treatment for AML - You do not have the IDH1 mutation - You have serious heart problems (specifically QT prolongation on ECG) - You have severe liver or kidney problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.